Human Pathology
Volume 41, Issue 2 , Pages 181-189 , February 2010

H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1

  • Christian Magerl

      Affiliations

    • Department of Pathology, University of Bonn, Sigmund-Freud-Straβe 25, 53127 Bonn, Germany
    • ,
  • Jörg Ellinger, MD

      Affiliations

    • Department of Urology, University of Bonn, Sigmund-Freud-Straβe 25, 53127 Bonn, Germany
    • ,
  • Till Braunschweig, MD

      Affiliations

    • Department of Pathology, University of Aachen, Pauwelsstraβe 30, 52074 Aachen, Germany
    • ,
  • Elisabeth Kremmer, MD

      Affiliations

    • GSF-Institute of Molecular Immunology, Marchioninistraβe 25, 81377 München, Germany
    • ,
  • Lin Kristin Koch, MD

      Affiliations

    • Department of Pathology, University of Bonn, Sigmund-Freud-Straβe 25, 53127 Bonn, Germany
    • ,
  • Tobias Höller

      Affiliations

    • Institute for Biometry, Informatics and Epidemiology, University of Bonn, Sigmund-Freud-Straβe 25, 53105 Bonn, Germany
    • ,
  • Reinhard Büttner, MD

      Affiliations

    • Department of Pathology, University of Bonn, Sigmund-Freud-Straβe 25, 53127 Bonn, Germany
    • ,
  • Bernhard Lüscher, PhD

      Affiliations

    • Department of Biochemistry and Molecular Biology, RWTH Aachen University, Pauwelsstraβe 30, 52057 Aachen, Germany
    • ,
  • Ines Gütgemann, MD

      Affiliations

    • Department of Pathology, University of Bonn, Sigmund-Freud-Straβe 25, 53127 Bonn, Germany
    • Corresponding Author InformationCorresponding author.

Received 3 January 2009 ,Revised 7 July 2009 ,Accepted 4 August 2009.

References 

  1. Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev. 2004;18:2315–2335
  2. Gibbons RJ. Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes. Hum Mol Genet. 2005;14:R85–R92
  3. Santos-Reboucas CB, Pimentel MM. Implication of abnormal epigenetic patterns for human diseases. Eur J Hum Genet. 2007;15:10–17
  4. Esteller M. CpG island methylation and histone modifications: biology and clinical significance. Ernst Schering Res Found Workshop. 2006;115–126
  5. Giles RH, Peters DJ, Breuning MH. Conjunction dysfunction: CBP/p300 in human disease. Trends Genet. 1998;14:178–183
  6. Gayther SA, Batley SJ, Linger L, et al. Mutations truncating the EP300 acetylase in human cancers. Nat Genet. 2000;24:300–303
  7. Kouzarides T. Histone methylation in transcriptional control. Curr Opin Genet Dev. 2002;12:198–209
  8. Zhang Y, Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev. 2001;15:2343–2360
  9. Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119:941–953
  10. Barlesi F, Giaccone G, Gallegos-Ruiz MI, et al. Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol. 2007;25:4358–4364
  11. Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005;435:1262–1266
  12. Luscher-Firzlaff J, Gawlista I, Vervoorts J, et al. The human trithorax protein hASH2 functions as an oncoprotein. Cancer Res. 2008;68:749–758
  13. Guccione E, Bassi C, Casadio F, et al. Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive. Nature. 2007;449:933–937
  14. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell. 2007;128:707–719
  15. Ruthenburg AJ, Allis CD, Wysocka J. Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol Cell. 2007;25:15–30
  16. Shi YJ, Matson C, Lan F, Iwase S, Baba T, Shi Y. Regulation of LSD1 histone demethylase activity by its associated factors. Mol Cell. 2005;19:857–864
  17. Metzger E, Wissmann M, Yin N, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 2005;437:436–439
  18. Kahl P, Gullotti L, Heukamp LC, et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 2006;66:11341–11347
  19. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844–847
  20. Heukamp LC, Fischer HP, Schirmacher P, et al. Podocalyxin-like protein 1 expression in primary hepatic tumours and tumour-like lesions. Histopathology. 2006;49:242–247
  21. Ney JT, Zhou H, Sipos B, et al. Podocalyxin-like protein 1 expression is useful to differentiate pancreatic ductal adenocarcinomas from adenocarcinomas of the biliary and gastrointestinal tracts. Hum Pathol. 2007;38:359–364
  22. Berg JP, Zhou Q, Breuhahn K, et al. Inverse expression of Jun activation domain binding protein 1 and cell cycle inhibitor p27Kip1: influence on proliferation in hepatocellular carcinoma. Hum Pathol. 2007;38:1621–1627
  23. Patil MA, Gutgemann I, Zhang J, et al. Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma. Carcinogenesis. 2005;26:2050–2057
  24. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987;8:138–140
  25. Steward MM, Lee JS, O'Donovan A, Wyatt M, Bernstein BE, Shilatifard A. Molecular regulation of H3K4 trimethylation by ASH2L, a shared subunit of MLL complexes. Nat Struct Mol Biol. 2006;13:852–854
  26. Kubicka S, Rudolph KL, Hanke M, et al. Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area. Liver. 2000;20:312–318
  27. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415–428
  28. Yu M, Schreek S, Cerni C, et al. PARP-10, a novel Myc-interacting protein with poly(ADP-ribose) polymerase activity, inhibits transformation. Oncogene. 2005;24:1982–1993
  29. Li SP, Wang HY, Li JQ, et al. Genome-wide analyses on loss of heterozygosity in hepatocellular carcinoma in Southern China. J Hepatol. 2001;34:840–849
  30. Nishimura T, Nishida N, Komeda T, Fukuda Y, Nakao K. Genotype stability and clonal evolution of hepatocellular carcinoma assessed by autopsy-based genome-wide microsatellite analysis. Cancer Genet Cytogenet. 2005;161:164–169
  31. Moinzadeh P, Breuhahn K, Stutzer H, Schirmacher P. Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade-results of an explorative CGH meta-analysis. Br J Cancer. 2005;92:935–941
  32. Nagai H, Pineau P, Tiollais P, Buendia MA, Dejean A. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene. 1997;14:2927–2933
  33. Buendia MA. Genetics of hepatocellular carcinoma. Semin Cancer Biol. 2000;10:185–200
  34. Kuroki T, Fujiwara Y, Tsuchiya E, et al. Accumulation of genetic changes during development and progression of hepatocellular carcinoma: loss of heterozygosity of chromosome arm 1p occurs at an early stage of hepatocarcinogenesis. Genes Chromosomes Cancer. 1995;13:163–167
  35. Pang JZ, Qin LX, Ren N, et al. Loss of heterozygosity at D8S298 is a predictor for long-term survival of patients with tumor-node-metastasis stage I of hepatocellular carcinoma. Clin Cancer Res. 2007;13:7363–7369

PII: S0046-8177(09)00293-7

doi: 10.1016/j.humpath.2009.08.007

Human Pathology
Volume 41, Issue 2 , Pages 181-189 , February 2010

Article Tools

* Image Usage & Resolution